Enjoy complimentary customisation on priority with our Enterprise License!
The antihypertensive drugs market size is forecast to increase by USD 6.23 billion at a CAGR of 3.27% between 2023 and 2028. Hypertension, a leading global health concern, drives the growth of the market. The market is witnessing significant trends, including the availability of a wide range of drugs catering to diverse patient needs and the growing adoption of personalized medicine. Moreover, the advent of wearable defibrillators and advanced monitoring devices is enabling early detection and effective management of hypertension, thereby increasing the demand for antihypertensive drugs. Diuretics, a common class of antihypertensive drugs, continue to dominate the market due to their effectiveness in managing fluid balance and reducing blood pressure. These trends and factors are expected to shape the growth trajectory of the market in the US.
Hypertension, or high blood pressure, is a common health condition affecting over 75 million Americans. Antihypertensive drugs are essential medications used to manage this condition. The market in the US includes various therapeutic classes such as diuretics, ACE inhibitors, vasodilators, calcium channel blockers, and beta-adrenergic blockers. The geriatric population, with their increased susceptibility to hypertension, significantly contributes to market growth. Sedentary lifestyles and unhealthy diets are major risk factors fueling the demand for antihypertensive drugs. Patent expirations of key drugs have led to an increase in generic offerings, making these medications more accessible and affordable.
Antihypertensive drugs are primarily distributed through retail pharmacies, hospitals, e-commerce websites, and online drug stores. Hospitals remain a significant market for these drugs due to their large patient base. The e-commerce sector is experiencing rapid growth, with online drug stores gaining popularity for their convenience and affordability. Calcium channel blockers and ACE inhibitors are currently the most widely used antihypertensive drugs. Diuretics, vasodilators, and beta-adrenergic blockers also hold considerable market share. The market in the US is expected to continue its growth trajectory, driven by the increasing prevalence of hypertension and the development of new therapeutic options.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The systemic hypertension segment is estimated to witness significant growth during the forecast period. Antihypertensive drugs play a significant role in managing systemic hypertension by decreasing systemic vascular resistance. Among various antihypertensive medications, diuretics have gained prominence due to their efficacy in reducing blood volume, cardiac output, and systemic vascular resistance. Hydrochlorothiazide, furosemide, and spironolactone are commonly used diuretics for treating hypertension. Additionally, adrenergic blockers like prazosin, terazosin, doxazosin, and trimazosin are employed to induce vasodilation in hypertensive patients. Furthermore, Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs) are widely used for the treatment of systemic hypertension.
Get a glance at the market share of various segments Request Free Sample
The systemic hypertension segment accounted for USD 28.07 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in the US and Canada is experiencing significant growth due to increasing awareness regarding hypertension. Organizations such as the Centers for Disease Control and Prevention (CDC) in the US and Hypertension Canada are actively educating the public about the risks, prevention, diagnosis, and treatment of high blood pressure. The region's market growth is also fueled by the presence of numerous pharmaceutical companies, including large players offering both branded and generic antihypertensive drugs. Additionally, a well-established regulatory framework facilitates the approval of new drugs in the region.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Availability of wide range of drugs is the key driver of the market. Antihypertensive medications are a crucial component in managing hypertension, a condition characterized by elevated blood pressure. These drugs function by decreasing blood volume, systemic vascular resistance, and cardiac output. Thiazide diuretics, such as Hydrochlorothiazide, are diuretic drugs that increase urine output by the kidney, thereby reducing blood volume. Valsartan tablets, a vasodilator drug, dilate blood vessels by relaxing smooth muscle, thereby reducing systemic vascular resistance. Cardioinhibitory drugs, like beta blockers, depress cardiac function by decreasing heart rate and myocardial contractility, thereby reducing cardiac output and arterial pressure. Centrally acting sympatholytic drugs, such as clonidine, block sympathetic activity by binding to and activating alpha2 adrenoceptors, thereby reducing sympathetic outflow to the heart and decreasing cardiac output by reducing heart rate and contractility.
The growing adoption of personalized medicine is the upcoming trend in the market. Modified-release formulations, including sustained-release and controlled-release tablets, play a crucial role in the treatment of hypertension. These formulations enable continuous 24-hour control of blood pressure by regulating the release of active ingredients, such as Valsartan and Thiazide diuretics like Hydrochlorothiazide. While sustained-release formulations maintain a consistent yet non-constant drug release, controlled-release formulations ensure a nearly constant drug release over an extended period. Pharmaceutical companies are increasingly focusing on developing these formulations to cater to the growing demand for effective hypertension treatments.
The advent of wearable defibrillators is a key challenge affecting the market growth. The market is experiencing significant research and development initiatives to create wearable cardiovascular defibrillators for managing cardiovascular symptoms. For example, the VEST (Vest Prevention of Early Sudden Death) trial tested the Zoll LifeVest wearable cardiovascular defibrillator in a randomized, multi-center study. This device aimed to assess its effectiveness in preventing sudden death among heart attack patients with an ejection fraction of 35% or less in the initial three months post-attack. Although ejection fractions typically improve in the months following a heart attack, the risk of sudden death remains elevated during this period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc: The company offers antihypertensive drugs such as Tenormin, Tenoretic, Zestril and Zestoretic.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Antihypertensive drugs are a crucial therapeutic class used for managing hypertension, a prevalent health condition affecting over 75 million Americans. The market for antihypertensive drugs in the US is significant, driven by the growing geriatric population and increasing prevalence of sedentary lifestyles. The market includes various types of antihypertensive drugs, such as diuretics, ACE inhibitors, vasodilators, calcium channel blockers, and beta-adrenergic blockers. Diuretics, including thiazide diuretics like hydrochlorothiazide and chlorthalidone, and indapamide, remain popular choices due to their effectiveness in reducing blood pressure. ACE inhibitors, such as Valsartan, are another essential class, inhibiting the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels and lowering blood pressure. Antihypertensive drugs are available in different settings, including retail pharmacies, hospital pharmacies, e-commerce websites, and online drug stores. Patent expirations of key drugs have led to increased competition and the entry of generic alternatives, impacting market dynamics.
Market Scope |
|
Report Coverage |
Details |
Page number |
143 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.27% |
Market growth 2024-2028 |
USD 6.23 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.13 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 55% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Hetero Healthcare Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Noden Pharma DAC, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.